Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.
Sergio Fragoso-SaavedraIsaac NúñezBelem M Audelo-CruzSarahi Arias-MartínezDaniel Manzur-SandovalAlejandro Quintero-VillegasH Benjamín García-GonzálezSergio L Carbajal-MorelosSergio PoncedeLeón-RosalesJosé Gotés-PalazuelosJosé A Maza-LarreaJ Javier Rosales-de la RosaDafne Diaz-RiveraEdgar Luna-GarcíaElvira Piten-IsidroPerla M Del Río-EstradaMario Fragoso-SaavedraYanink Caro-VegaIsabella BatinaLeón Islas-WeinsteinDavid A Iruegas-NunezJuan J CalvaPablo F Belaunzarán-ZamudioJuan Sierra-MaderoJosé C CrispínSergio Iván Valdés-FerrerPublished in: Molecular medicine (Cambridge, Mass.) (2022)
Our data indicate that adding pyridostigmine to standard care reduces mortality among patients hospitalized for severe COVID-19.
Keyphrases
- randomized controlled trial
- cardiovascular events
- coronavirus disease
- early onset
- sars cov
- healthcare
- palliative care
- risk factors
- study protocol
- respiratory syndrome coronavirus
- electronic health record
- quality improvement
- cardiovascular disease
- type diabetes
- big data
- pain management
- coronary artery disease
- drug induced
- machine learning
- affordable care act
- deep learning